Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-EB-TATE in advanced metastatic neuroendocrine tumors
NCT03308682Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2017
- Primary completion
- May 2018
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EBTATE in neuroendocrine tumors (NETs), sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized Uptake Value at 168 hours. Status: unknown.
02
Drugs
EBTATE
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03308682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308682.